Free Trial
NYSE:CHRO

Chromocell Therapeutics 8/13/2024 Earnings Report

Chromocell Therapeutics logo
$1.35 -0.01 (-0.74%)
Closing price 04/28/2025 04:00 PM Eastern
Extended Trading
$1.34 -0.01 (-0.74%)
As of 05:53 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Chromocell Therapeutics EPS Results

Actual EPS
-$0.31
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Chromocell Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Chromocell Therapeutics Announcement Details

Quarter
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Chromocell Therapeutics Earnings Headlines

Ligand subsidiaries, Chromocell Therapeutics to merge
Warning: “DOGE Collapse” imminent
Elon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week, President Trump promised to buy a Tesla to help support Musk in the face of a boycott against his company. But according to one research group, with connections to the Pentagon and the U.S. government, Elon's preparing to strike back in a much bigger way in the days ahead.
Chromocell Therapeutics Corp (CHRO)
See More Chromocell Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Chromocell Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Chromocell Therapeutics and other key companies, straight to your email.

About Chromocell Therapeutics

Chromocell Therapeutics (NYSE:CHRO), a clinical-stage biotech company, focuses on the development and commercialization of new therapeutics to alleviate pain. The company intends to selectively target the sodium ion-channel known as NaV1.7, as well as other receptors in the NaV family. Its lead compound comprises CC8464, which is in Phase 2a clinical trials for use in the treatment of erythromelalgia, as well as other fields of neuropathic pain and acute and chronic eye pain. Chromocell Therapeutics Corporation was founded in 2002 and is based in Freehold, New Jersey.

View Chromocell Therapeutics Profile

More Earnings Resources from MarketBeat